Peter Kabos
Concepts (401)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 52 | 2025 | 2132 | 5.870 |
Why?
| Receptors, Estrogen | 21 | 2025 | 424 | 3.110 |
Why?
| Receptor, ErbB-2 | 14 | 2024 | 325 | 2.020 |
Why?
| Receptors, Progesterone | 11 | 2020 | 341 | 1.260 |
Why?
| Brain Neoplasms | 14 | 2023 | 1163 | 1.010 |
Why?
| Keratin-5 | 6 | 2022 | 49 | 0.850 |
Why?
| Triple Negative Breast Neoplasms | 6 | 2023 | 191 | 0.830 |
Why?
| Estrogens | 7 | 2023 | 342 | 0.820 |
Why?
| Breast Neoplasms, Male | 3 | 2018 | 29 | 0.790 |
Why?
| Biomarkers, Tumor | 7 | 2022 | 1181 | 0.790 |
Why?
| Stem Cells | 8 | 2006 | 578 | 0.770 |
Why?
| Antineoplastic Agents, Hormonal | 7 | 2025 | 158 | 0.730 |
Why?
| Tetrahydronaphthalenes | 1 | 2021 | 29 | 0.710 |
Why?
| Estrogen Receptor alpha | 4 | 2024 | 132 | 0.710 |
Why?
| Drug Resistance, Neoplasm | 5 | 2025 | 749 | 0.700 |
Why?
| Neoplasm Metastasis | 4 | 2020 | 608 | 0.700 |
Why?
| Immunoprecipitation | 4 | 2020 | 157 | 0.680 |
Why?
| Neoplastic Cells, Circulating | 1 | 2020 | 70 | 0.670 |
Why?
| Benzodiazepines | 1 | 2021 | 129 | 0.670 |
Why?
| Neurons | 8 | 2004 | 1448 | 0.660 |
Why?
| Radiosurgery | 3 | 2023 | 318 | 0.660 |
Why?
| Brain Edema | 2 | 2023 | 60 | 0.650 |
Why?
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2017 | 54 | 0.620 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2020 | 199 | 0.610 |
Why?
| Leukocytes, Mononuclear | 2 | 2020 | 539 | 0.600 |
Why?
| Gene Expression Regulation, Neoplastic | 11 | 2025 | 1351 | 0.570 |
Why?
| Gene Expression Profiling | 7 | 2020 | 1688 | 0.570 |
Why?
| Fanconi Anemia Complementation Group N Protein | 1 | 2017 | 5 | 0.550 |
Why?
| Polyadenylation | 1 | 2017 | 40 | 0.550 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2024 | 1559 | 0.550 |
Why?
| High-Throughput Nucleotide Sequencing | 4 | 2019 | 484 | 0.540 |
Why?
| Female | 54 | 2025 | 68154 | 0.540 |
Why?
| Organoplatinum Compounds | 1 | 2016 | 40 | 0.540 |
Why?
| Neoplastic Stem Cells | 7 | 2020 | 386 | 0.540 |
Why?
| Carcinogenesis | 2 | 2020 | 209 | 0.540 |
Why?
| Cancer-Associated Fibroblasts | 1 | 2016 | 13 | 0.530 |
Why?
| Fluorouracil | 1 | 2016 | 197 | 0.500 |
Why?
| Artifacts | 1 | 2016 | 123 | 0.500 |
Why?
| CD146 Antigen | 3 | 2021 | 41 | 0.490 |
Why?
| Mitochondrial Proteins | 1 | 2017 | 244 | 0.480 |
Why?
| Thrombocytopenia | 1 | 2016 | 181 | 0.470 |
Why?
| MCF-7 Cells | 4 | 2020 | 115 | 0.460 |
Why?
| Maytansine | 1 | 2014 | 16 | 0.460 |
Why?
| Cell Line, Tumor | 15 | 2025 | 3184 | 0.450 |
Why?
| Humans | 67 | 2025 | 128418 | 0.440 |
Why?
| Analgesics, Opioid | 1 | 2021 | 887 | 0.410 |
Why?
| Trastuzumab | 5 | 2023 | 100 | 0.410 |
Why?
| Binding Sites | 1 | 2016 | 1236 | 0.410 |
Why?
| RNA-Binding Proteins | 1 | 2016 | 388 | 0.400 |
Why?
| Tumor Microenvironment | 4 | 2021 | 623 | 0.400 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2014 | 215 | 0.400 |
Why?
| Neoplasms, Hormone-Dependent | 1 | 2012 | 38 | 0.400 |
Why?
| Antineoplastic Agents | 4 | 2023 | 2051 | 0.390 |
Why?
| Tamoxifen | 5 | 2025 | 200 | 0.390 |
Why?
| Homeodomain Proteins | 5 | 2018 | 490 | 0.380 |
Why?
| Piperazines | 2 | 2024 | 336 | 0.370 |
Why?
| Neoplasm Recurrence, Local | 5 | 2021 | 958 | 0.370 |
Why?
| MicroRNAs | 5 | 2016 | 677 | 0.370 |
Why?
| Chemotherapy, Adjuvant | 5 | 2023 | 376 | 0.370 |
Why?
| Protein Kinase Inhibitors | 5 | 2021 | 872 | 0.360 |
Why?
| RNA | 2 | 2016 | 880 | 0.360 |
Why?
| Estradiol | 3 | 2015 | 486 | 0.360 |
Why?
| Neoadjuvant Therapy | 3 | 2021 | 381 | 0.350 |
Why?
| Mutation | 3 | 2021 | 3689 | 0.350 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 755 | 0.340 |
Why?
| Liver Neoplasms | 1 | 2015 | 633 | 0.340 |
Why?
| Pyridines | 2 | 2024 | 475 | 0.340 |
Why?
| Progestins | 5 | 2020 | 78 | 0.340 |
Why?
| Pyrimidines | 3 | 2018 | 445 | 0.320 |
Why?
| Colorectal Neoplasms | 1 | 2016 | 746 | 0.320 |
Why?
| Tumor Cells, Cultured | 7 | 2020 | 930 | 0.320 |
Why?
| Prognosis | 7 | 2021 | 3772 | 0.310 |
Why?
| Carcinoma, Ductal, Breast | 2 | 2020 | 82 | 0.310 |
Why?
| Adenocarcinoma | 1 | 2015 | 888 | 0.300 |
Why?
| Hydrocephalus | 3 | 2023 | 108 | 0.300 |
Why?
| Bone Marrow Cells | 2 | 2014 | 294 | 0.290 |
Why?
| Signal Transduction | 5 | 2018 | 4826 | 0.280 |
Why?
| Middle Aged | 16 | 2024 | 30889 | 0.280 |
Why?
| Neoplasm Staging | 4 | 2021 | 1290 | 0.270 |
Why?
| Astrocytes | 5 | 2023 | 188 | 0.270 |
Why?
| Helix-Loop-Helix Motifs | 2 | 2002 | 12 | 0.260 |
Why?
| Necrosis | 2 | 2019 | 229 | 0.250 |
Why?
| Cluster Analysis | 4 | 2019 | 478 | 0.250 |
Why?
| Chondroitin Sulfate Proteoglycans | 2 | 2006 | 10 | 0.250 |
Why?
| Sequence Analysis, RNA | 2 | 2019 | 429 | 0.240 |
Why?
| Fatty Acid Synthase, Type I | 1 | 2025 | 11 | 0.240 |
Why?
| Neuroglia | 2 | 2003 | 166 | 0.240 |
Why?
| Neoplasm Grading | 2 | 2017 | 283 | 0.230 |
Why?
| Aged | 14 | 2024 | 21953 | 0.230 |
Why?
| Genetic Therapy | 2 | 2003 | 290 | 0.230 |
Why?
| Mice, Inbred NOD | 5 | 2021 | 586 | 0.230 |
Why?
| Aromatase Inhibitors | 2 | 2021 | 51 | 0.230 |
Why?
| Disease-Free Survival | 4 | 2024 | 647 | 0.220 |
Why?
| Carbolines | 1 | 2024 | 27 | 0.220 |
Why?
| Triazines | 1 | 2024 | 38 | 0.220 |
Why?
| Adult | 16 | 2024 | 35300 | 0.220 |
Why?
| Animals | 27 | 2021 | 34479 | 0.220 |
Why?
| Progesterone | 3 | 2014 | 242 | 0.220 |
Why?
| Morpholines | 1 | 2024 | 122 | 0.210 |
Why?
| Extracellular Matrix Proteins | 1 | 2004 | 140 | 0.210 |
Why?
| Mice | 19 | 2021 | 16602 | 0.210 |
Why?
| Glioma | 5 | 2006 | 353 | 0.210 |
Why?
| Keratin-17 | 1 | 2022 | 4 | 0.200 |
Why?
| Aquaporin 4 | 2 | 2023 | 96 | 0.200 |
Why?
| Nerve Regeneration | 1 | 2002 | 62 | 0.200 |
Why?
| Stromal Cells | 2 | 2020 | 105 | 0.200 |
Why?
| Triglycerides | 1 | 2025 | 523 | 0.200 |
Why?
| Mice, SCID | 4 | 2020 | 350 | 0.200 |
Why?
| Tumor Suppressor Proteins | 2 | 2015 | 313 | 0.200 |
Why?
| Immunoconjugates | 1 | 2023 | 101 | 0.200 |
Why?
| Down-Regulation | 4 | 2015 | 631 | 0.200 |
Why?
| Cell-Free Nucleic Acids | 1 | 2022 | 31 | 0.190 |
Why?
| Neoplasm Invasiveness | 3 | 2020 | 480 | 0.190 |
Why?
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2021 | 5 | 0.190 |
Why?
| Medicare | 3 | 2023 | 715 | 0.190 |
Why?
| Lipid Metabolism | 1 | 2025 | 491 | 0.190 |
Why?
| Cyclins | 1 | 2002 | 85 | 0.190 |
Why?
| Aged, 80 and over | 4 | 2024 | 7033 | 0.180 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2015 | 508 | 0.180 |
Why?
| Gene Regulatory Networks | 2 | 2014 | 280 | 0.180 |
Why?
| gamma-Aminobutyric Acid | 1 | 2002 | 158 | 0.180 |
Why?
| Insulin Receptor Substrate Proteins | 1 | 2020 | 59 | 0.180 |
Why?
| Cell Adhesion Molecules | 1 | 2021 | 172 | 0.180 |
Why?
| RNA, Messenger | 3 | 2019 | 2675 | 0.180 |
Why?
| Cancer Care Facilities | 1 | 2020 | 32 | 0.170 |
Why?
| Meningeal Carcinomatosis | 1 | 2020 | 8 | 0.170 |
Why?
| Hyaluronan Receptors | 4 | 2014 | 97 | 0.170 |
Why?
| Antineoplastic Agents, Immunological | 2 | 2019 | 175 | 0.170 |
Why?
| SEER Program | 1 | 2021 | 206 | 0.170 |
Why?
| Carcinoma, Lobular | 1 | 2020 | 48 | 0.170 |
Why?
| Cell Proliferation | 6 | 2025 | 2344 | 0.170 |
Why?
| Transcriptome | 2 | 2019 | 881 | 0.170 |
Why?
| Aminopyridines | 1 | 2020 | 96 | 0.170 |
Why?
| Gene Library | 2 | 2019 | 115 | 0.170 |
Why?
| Collagen | 2 | 2020 | 429 | 0.160 |
Why?
| Repressor Proteins | 1 | 2002 | 399 | 0.160 |
Why?
| Retrospective Studies | 5 | 2023 | 14454 | 0.160 |
Why?
| Lymphatic Metastasis | 2 | 2017 | 318 | 0.160 |
Why?
| Benzimidazoles | 1 | 2020 | 157 | 0.160 |
Why?
| Antigens, Neoplasm | 1 | 2021 | 309 | 0.160 |
Why?
| ErbB Receptors | 2 | 2020 | 601 | 0.160 |
Why?
| Paclitaxel | 1 | 2020 | 214 | 0.150 |
Why?
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 52 | 0.150 |
Why?
| beta Catenin | 1 | 2020 | 219 | 0.150 |
Why?
| Xenograft Model Antitumor Assays | 4 | 2017 | 814 | 0.140 |
Why?
| Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 81 | 0.140 |
Why?
| Heterografts | 4 | 2020 | 129 | 0.140 |
Why?
| Treatment Outcome | 5 | 2023 | 10152 | 0.140 |
Why?
| RNA Polymerase III | 1 | 2017 | 26 | 0.140 |
Why?
| Disease Progression | 4 | 2018 | 2602 | 0.140 |
Why?
| 3' Untranslated Regions | 1 | 2017 | 140 | 0.130 |
Why?
| Pyrroles | 1 | 2017 | 191 | 0.130 |
Why?
| Neoplasms, Radiation-Induced | 1 | 2016 | 71 | 0.130 |
Why?
| Genital Neoplasms, Female | 1 | 2017 | 81 | 0.130 |
Why?
| Single-Cell Analysis | 1 | 2019 | 272 | 0.130 |
Why?
| Receptors, Androgen | 1 | 2017 | 143 | 0.130 |
Why?
| Gene Expression | 2 | 2016 | 1456 | 0.120 |
Why?
| Ovary | 1 | 2017 | 210 | 0.120 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 940 | 0.120 |
Why?
| Ribosomal Proteins | 1 | 2015 | 77 | 0.120 |
Why?
| Combined Modality Therapy | 2 | 2019 | 1204 | 0.120 |
Why?
| Neoplasms, Second Primary | 1 | 2016 | 108 | 0.120 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 421 | 0.120 |
Why?
| Paracrine Communication | 1 | 2015 | 60 | 0.120 |
Why?
| DNA Primers | 1 | 2016 | 510 | 0.120 |
Why?
| Risk Reduction Behavior | 1 | 2016 | 209 | 0.120 |
Why?
| Pyrazoles | 1 | 2018 | 404 | 0.120 |
Why?
| Hodgkin Disease | 1 | 2016 | 134 | 0.120 |
Why?
| Fibroblasts | 1 | 2020 | 935 | 0.120 |
Why?
| Reactive Oxygen Species | 1 | 2017 | 577 | 0.120 |
Why?
| Obesity | 2 | 2018 | 2858 | 0.120 |
Why?
| Azepines | 1 | 2015 | 88 | 0.120 |
Why?
| STAT5 Transcription Factor | 1 | 2014 | 48 | 0.110 |
Why?
| Peptides | 1 | 2020 | 908 | 0.110 |
Why?
| Odds Ratio | 1 | 2017 | 1023 | 0.110 |
Why?
| Clinical Decision-Making | 1 | 2017 | 304 | 0.110 |
Why?
| Receptors, Steroid | 1 | 2014 | 48 | 0.110 |
Why?
| Apoptosis | 4 | 2017 | 2435 | 0.110 |
Why?
| Opioid-Related Disorders | 1 | 2021 | 480 | 0.110 |
Why?
| Disease Models, Animal | 4 | 2017 | 3937 | 0.100 |
Why?
| Sensitivity and Specificity | 2 | 2016 | 1815 | 0.100 |
Why?
| DNA-Binding Proteins | 2 | 2015 | 1421 | 0.100 |
Why?
| CD24 Antigen | 1 | 2012 | 20 | 0.100 |
Why?
| RNA Interference | 1 | 2014 | 441 | 0.100 |
Why?
| Retinoids | 1 | 2012 | 34 | 0.100 |
Why?
| Anthracyclines | 2 | 2023 | 46 | 0.100 |
Why?
| Cell Differentiation | 4 | 2004 | 1900 | 0.100 |
Why?
| Clinical Trials as Topic | 1 | 2017 | 993 | 0.100 |
Why?
| Comorbidity | 1 | 2017 | 1543 | 0.100 |
Why?
| Taxoids | 2 | 2023 | 95 | 0.100 |
Why?
| Male | 8 | 2018 | 62858 | 0.100 |
Why?
| Doxorubicin | 3 | 2022 | 322 | 0.100 |
Why?
| United States | 4 | 2023 | 13830 | 0.090 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 163 | 0.090 |
Why?
| Small Molecule Libraries | 1 | 2012 | 86 | 0.090 |
Why?
| Genome, Human | 1 | 2014 | 391 | 0.090 |
Why?
| Rats | 5 | 2017 | 5165 | 0.090 |
Why?
| Mitochondria | 1 | 2017 | 848 | 0.090 |
Why?
| Drug Discovery | 1 | 2012 | 130 | 0.090 |
Why?
| Tumor Burden | 1 | 2012 | 283 | 0.090 |
Why?
| Logistic Models | 1 | 2016 | 1974 | 0.090 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2002 | 230 | 0.090 |
Why?
| Time Factors | 3 | 2020 | 6482 | 0.090 |
Why?
| Lung Neoplasms | 1 | 2023 | 2328 | 0.090 |
Why?
| Nuclear Proteins | 1 | 2015 | 657 | 0.080 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 756 | 0.080 |
Why?
| Dendritic Cells | 2 | 2004 | 479 | 0.080 |
Why?
| Estrogen Antagonists | 1 | 2010 | 45 | 0.080 |
Why?
| Protein Binding | 1 | 2016 | 2103 | 0.080 |
Why?
| Transforming Growth Factor beta | 1 | 2012 | 445 | 0.080 |
Why?
| Administration, Oral | 2 | 2024 | 754 | 0.080 |
Why?
| BRCA2 Protein | 1 | 2009 | 53 | 0.080 |
Why?
| Cell Culture Techniques | 2 | 2020 | 345 | 0.080 |
Why?
| Thrombophilia | 1 | 2009 | 66 | 0.080 |
Why?
| Pregnancy Complications, Neoplastic | 1 | 2009 | 52 | 0.080 |
Why?
| Receptors, CXCR4 | 2 | 2006 | 82 | 0.080 |
Why?
| Quinolines | 2 | 2021 | 153 | 0.080 |
Why?
| Practice Patterns, Physicians' | 1 | 2017 | 1258 | 0.080 |
Why?
| Cells, Cultured | 3 | 2006 | 4001 | 0.070 |
Why?
| Cell Movement | 3 | 2015 | 936 | 0.070 |
Why?
| Brain | 2 | 2023 | 2620 | 0.070 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2002 | 1185 | 0.070 |
Why?
| Stem Cell Transplantation | 3 | 2004 | 165 | 0.070 |
Why?
| Rats, Sprague-Dawley | 2 | 2002 | 2239 | 0.070 |
Why?
| Genetic Predisposition to Disease | 1 | 2016 | 2264 | 0.070 |
Why?
| Proteoglycans | 2 | 2006 | 109 | 0.070 |
Why?
| Radiotherapy, Adjuvant | 2 | 2018 | 209 | 0.070 |
Why?
| Risk Factors | 2 | 2020 | 9704 | 0.070 |
Why?
| Drug Delivery Systems | 1 | 2010 | 325 | 0.070 |
Why?
| Immunohistochemistry | 2 | 2017 | 1664 | 0.070 |
Why?
| Aurora Kinase A | 2 | 2018 | 55 | 0.070 |
Why?
| Severity of Illness Index | 1 | 2014 | 2722 | 0.060 |
Why?
| Biopsy | 2 | 2020 | 1081 | 0.060 |
Why?
| Nervous System | 1 | 2006 | 66 | 0.060 |
Why?
| Rats, Inbred F344 | 2 | 2003 | 251 | 0.060 |
Why?
| Tomography, X-Ray Computed | 1 | 2015 | 2523 | 0.060 |
Why?
| Mass Spectrometry | 2 | 2020 | 659 | 0.060 |
Why?
| Neoplasm Transplantation | 2 | 2016 | 258 | 0.060 |
Why?
| Infant, Premature, Diseases | 1 | 2006 | 93 | 0.060 |
Why?
| Receptor-Like Protein Tyrosine Phosphatases, Class 5 | 1 | 2004 | 1 | 0.060 |
Why?
| Aggrecans | 1 | 2004 | 14 | 0.060 |
Why?
| Lectins, C-Type | 1 | 2004 | 64 | 0.060 |
Why?
| Isoquinolines | 1 | 2024 | 41 | 0.060 |
Why?
| Azetidines | 1 | 2024 | 40 | 0.060 |
Why?
| Cyclophosphamide | 2 | 2018 | 227 | 0.060 |
Why?
| Maximum Tolerated Dose | 1 | 2024 | 192 | 0.050 |
Why?
| Adipose Tissue | 2 | 2018 | 589 | 0.050 |
Why?
| Cell Line | 2 | 2014 | 2731 | 0.050 |
Why?
| Hemangioma, Cavernous, Central Nervous System | 1 | 2003 | 6 | 0.050 |
Why?
| Mastectomy, Segmental | 2 | 2017 | 85 | 0.050 |
Why?
| Glioblastoma | 2 | 2006 | 322 | 0.050 |
Why?
| Mice, Inbred C57BL | 5 | 2004 | 5272 | 0.050 |
Why?
| Aromatase | 1 | 2023 | 31 | 0.050 |
Why?
| Inhibitor of Differentiation Protein 1 | 1 | 2002 | 6 | 0.050 |
Why?
| Inhibitor of Differentiation Protein 2 | 1 | 2002 | 5 | 0.050 |
Why?
| Camptothecin | 1 | 2023 | 106 | 0.050 |
Why?
| Neoplasms, Multiple Primary | 1 | 2003 | 54 | 0.050 |
Why?
| Edema | 1 | 2023 | 125 | 0.050 |
Why?
| Pyramidal Tracts | 1 | 2002 | 26 | 0.050 |
Why?
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2022 | 8 | 0.050 |
Why?
| Neurites | 1 | 2002 | 46 | 0.050 |
Why?
| Sciatic Nerve | 1 | 2002 | 60 | 0.050 |
Why?
| Gonadotropin-Releasing Hormone | 1 | 2024 | 207 | 0.050 |
Why?
| Transcription Factor HES-1 | 1 | 2002 | 5 | 0.050 |
Why?
| Vimentin | 1 | 2022 | 50 | 0.050 |
Why?
| Interleukin-12 | 1 | 2002 | 119 | 0.050 |
Why?
| Phenotype | 1 | 2010 | 3044 | 0.050 |
Why?
| Blotting, Western | 1 | 2004 | 1164 | 0.050 |
Why?
| Frontal Lobe | 1 | 2002 | 153 | 0.050 |
Why?
| Oligonucleotides, Antisense | 1 | 2002 | 106 | 0.050 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2002 | 114 | 0.050 |
Why?
| Fibroblast Growth Factors | 1 | 2002 | 170 | 0.050 |
Why?
| Mice, Inbred BALB C | 1 | 2004 | 1228 | 0.050 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2024 | 380 | 0.050 |
Why?
| Ependymoma | 1 | 2003 | 176 | 0.050 |
Why?
| Neoplasms | 1 | 2015 | 2464 | 0.050 |
Why?
| Protein-Lysine 6-Oxidase | 1 | 2020 | 8 | 0.050 |
Why?
| Cerebral Cortex | 1 | 2004 | 423 | 0.040 |
Why?
| Nucleosomes | 1 | 2022 | 137 | 0.040 |
Why?
| Clinical Trials, Phase I as Topic | 1 | 2020 | 50 | 0.040 |
Why?
| Hospitals, University | 1 | 2021 | 176 | 0.040 |
Why?
| Nervous System Diseases | 1 | 2003 | 252 | 0.040 |
Why?
| Animals, Newborn | 1 | 2002 | 803 | 0.040 |
Why?
| Membrane Glycoproteins | 1 | 2002 | 466 | 0.040 |
Why?
| Adherens Junctions | 1 | 2020 | 26 | 0.040 |
Why?
| Dose-Response Relationship, Drug | 1 | 2024 | 1936 | 0.040 |
Why?
| Gene Knockout Techniques | 1 | 2020 | 109 | 0.040 |
Why?
| Protein Interaction Mapping | 1 | 2020 | 107 | 0.040 |
Why?
| Kaplan-Meier Estimate | 1 | 2021 | 853 | 0.040 |
Why?
| Interferon-gamma | 1 | 2002 | 759 | 0.040 |
Why?
| Mice, Nude | 2 | 2015 | 682 | 0.040 |
Why?
| DNA, Complementary | 1 | 2019 | 267 | 0.040 |
Why?
| beta-Galactosidase | 3 | 2002 | 75 | 0.040 |
Why?
| Loss of Function Mutation | 1 | 2018 | 39 | 0.040 |
Why?
| Immunotherapy | 1 | 2003 | 587 | 0.040 |
Why?
| Maintenance Chemotherapy | 1 | 2018 | 22 | 0.040 |
Why?
| Cadherins | 1 | 2020 | 186 | 0.040 |
Why?
| Wnt Signaling Pathway | 1 | 2020 | 165 | 0.040 |
Why?
| Nausea | 1 | 2018 | 107 | 0.040 |
Why?
| Promoter Regions, Genetic | 2 | 2012 | 1198 | 0.040 |
Why?
| Breast | 1 | 2018 | 152 | 0.040 |
Why?
| Mastectomy | 1 | 2018 | 131 | 0.030 |
Why?
| Phenylthiohydantoin | 1 | 2017 | 44 | 0.030 |
Why?
| Diarrhea | 1 | 2018 | 177 | 0.030 |
Why?
| Antigens, CD | 1 | 2020 | 482 | 0.030 |
Why?
| Mammary Neoplasms, Experimental | 1 | 2017 | 66 | 0.030 |
Why?
| Area Under Curve | 1 | 2017 | 279 | 0.030 |
Why?
| Ovariectomy | 1 | 2017 | 136 | 0.030 |
Why?
| Nitriles | 1 | 2017 | 157 | 0.030 |
Why?
| Steroids | 1 | 2017 | 147 | 0.030 |
Why?
| Benzamides | 1 | 2017 | 194 | 0.030 |
Why?
| Fatigue | 1 | 2018 | 317 | 0.030 |
Why?
| Cell Membrane | 1 | 2020 | 720 | 0.030 |
Why?
| Flow Cytometry | 2 | 2012 | 1142 | 0.030 |
Why?
| Apoptosis Regulatory Proteins | 2 | 2009 | 182 | 0.030 |
Why?
| Chromatography, Liquid | 1 | 2017 | 374 | 0.030 |
Why?
| Proto-Oncogene Proteins c-mdm2 | 1 | 2015 | 63 | 0.030 |
Why?
| Postmenopause | 1 | 2017 | 348 | 0.030 |
Why?
| Tumor Protein p73 | 1 | 2015 | 14 | 0.030 |
Why?
| Transcription Factors | 1 | 2002 | 1628 | 0.030 |
Why?
| Weight Gain | 1 | 2018 | 503 | 0.030 |
Why?
| Gene Knockdown Techniques | 1 | 2015 | 312 | 0.030 |
Why?
| Molecular Targeted Therapy | 1 | 2017 | 385 | 0.030 |
Why?
| Jagged-1 Protein | 1 | 2014 | 22 | 0.030 |
Why?
| Serrate-Jagged Proteins | 1 | 2014 | 27 | 0.030 |
Why?
| Argonaute Proteins | 1 | 2014 | 28 | 0.030 |
Why?
| Wnt-5a Protein | 1 | 2014 | 21 | 0.030 |
Why?
| Software | 1 | 2019 | 608 | 0.030 |
Why?
| Matrix Metalloproteinase 2 | 1 | 2014 | 55 | 0.030 |
Why?
| Testosterone | 1 | 2017 | 373 | 0.030 |
Why?
| Transcription, Genetic | 1 | 2020 | 1404 | 0.030 |
Why?
| Cellular Microenvironment | 1 | 2014 | 80 | 0.030 |
Why?
| Interleukin-6 | 1 | 2017 | 716 | 0.030 |
Why?
| Cell Transformation, Neoplastic | 1 | 2015 | 325 | 0.030 |
Why?
| Wnt Proteins | 1 | 2014 | 126 | 0.030 |
Why?
| Guideline Adherence | 1 | 2017 | 521 | 0.030 |
Why?
| Gene Expression Regulation | 1 | 2022 | 2505 | 0.030 |
Why?
| Socioeconomic Factors | 1 | 2017 | 1212 | 0.030 |
Why?
| Acitretin | 1 | 2012 | 3 | 0.030 |
Why?
| Miconazole | 1 | 2012 | 5 | 0.030 |
Why?
| Calcium-Binding Proteins | 1 | 2014 | 210 | 0.030 |
Why?
| Isotretinoin | 1 | 2012 | 23 | 0.020 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 371 | 0.020 |
Why?
| Luciferases | 1 | 2012 | 147 | 0.020 |
Why?
| Genes, Reporter | 1 | 2012 | 265 | 0.020 |
Why?
| Biomarkers | 2 | 2017 | 3880 | 0.020 |
Why?
| Tretinoin | 1 | 2012 | 128 | 0.020 |
Why?
| Magnetic Resonance Imaging | 2 | 2019 | 3376 | 0.020 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2014 | 500 | 0.020 |
Why?
| Risk Assessment | 1 | 2020 | 3232 | 0.020 |
Why?
| Green Fluorescent Proteins | 1 | 2012 | 380 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2020 | 4892 | 0.020 |
Why?
| Diet | 1 | 2018 | 1199 | 0.020 |
Why?
| Colorado | 1 | 2020 | 4375 | 0.020 |
Why?
| Proto-Oncogene Proteins | 1 | 2014 | 634 | 0.020 |
Why?
| Base Sequence | 1 | 2014 | 2135 | 0.020 |
Why?
| HEK293 Cells | 1 | 2012 | 683 | 0.020 |
Why?
| Age Factors | 1 | 2017 | 3103 | 0.020 |
Why?
| Practice Guidelines as Topic | 1 | 2017 | 1478 | 0.020 |
Why?
| Pregnancy Trimester, Second | 1 | 2009 | 78 | 0.020 |
Why?
| Molecular Sequence Data | 1 | 2014 | 2819 | 0.020 |
Why?
| Hypertension | 1 | 2018 | 1235 | 0.020 |
Why?
| Pregnancy Trimester, First | 1 | 2009 | 138 | 0.020 |
Why?
| Endothelial Cells | 1 | 2014 | 698 | 0.020 |
Why?
| Lymph Node Excision | 1 | 2009 | 165 | 0.020 |
Why?
| Transplantation, Heterologous | 1 | 2008 | 187 | 0.020 |
Why?
| Membrane Proteins | 1 | 2014 | 1105 | 0.020 |
Why?
| Neoplasms, Experimental | 1 | 2008 | 169 | 0.020 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 2002 | 846 | 0.020 |
Why?
| Infant, Newborn | 2 | 2009 | 5687 | 0.020 |
Why?
| CD4-Positive T-Lymphocytes | 2 | 2002 | 1046 | 0.020 |
Why?
| Chemokines, CXC | 1 | 2006 | 68 | 0.020 |
Why?
| Nestin | 1 | 2006 | 19 | 0.020 |
Why?
| Laminin | 1 | 2006 | 68 | 0.020 |
Why?
| Intermediate Filament Proteins | 1 | 2006 | 57 | 0.020 |
Why?
| Chemokine CXCL12 | 1 | 2006 | 77 | 0.020 |
Why?
| Glial Fibrillary Acidic Protein | 1 | 2006 | 92 | 0.020 |
Why?
| Lasers | 1 | 2006 | 132 | 0.020 |
Why?
| Drug Combinations | 1 | 2006 | 323 | 0.010 |
Why?
| Adolescent | 1 | 2024 | 20179 | 0.010 |
Why?
| Culture Media, Conditioned | 1 | 2004 | 108 | 0.010 |
Why?
| RNA, Small Interfering | 1 | 2006 | 571 | 0.010 |
Why?
| Injections, Intralesional | 1 | 2003 | 34 | 0.010 |
Why?
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 43 | 0.010 |
Why?
| 3T3 Cells | 1 | 2002 | 151 | 0.010 |
Why?
| Random Allocation | 1 | 2003 | 343 | 0.010 |
Why?
| Nerve Tissue Proteins | 1 | 2006 | 567 | 0.010 |
Why?
| Models, Neurological | 1 | 2004 | 236 | 0.010 |
Why?
| Adenoviridae | 1 | 2002 | 189 | 0.010 |
Why?
| Infant, Premature | 1 | 2006 | 535 | 0.010 |
Why?
| Reference Values | 1 | 2003 | 776 | 0.010 |
Why?
| Genetic Vectors | 1 | 2002 | 311 | 0.010 |
Why?
| Oligodendroglia | 1 | 2002 | 166 | 0.010 |
Why?
| Transfection | 1 | 2002 | 893 | 0.010 |
Why?
| Recombinant Fusion Proteins | 1 | 2002 | 634 | 0.010 |
Why?
| Survival Rate | 1 | 2003 | 1869 | 0.010 |
Why?
| Case-Control Studies | 1 | 2006 | 3328 | 0.010 |
Why?
| Pregnancy | 1 | 2009 | 6357 | 0.010 |
Why?
| Vaccination | 1 | 2003 | 1346 | 0.010 |
Why?
| Prospective Studies | 1 | 2006 | 7036 | 0.010 |
Why?
| Infant | 1 | 2006 | 8914 | 0.010 |
Why?
|
|
Kabos's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|